What is Forge Biologics?
Headquartered in Ohio, Forge Biologics operates as a specialized hybrid entity, functioning simultaneously as a contract development and manufacturing organization (CDMO) and a therapeutic development firm. Since its inception in 2020, the company has addressed the acute industry bottleneck in viral vector manufacturing, providing essential services that accelerate the path to clinical trials for gene therapy developers. Its dual-model approach allows for both the generation of steady-state revenue through manufacturing partnerships and the long-term value creation inherent in its proprietary pipeline of genetic medicines.
How much funding has Forge Biologics raised?
Forge Biologics has raised a total of $330M across 4 funding rounds:
Series A
$40M
Series B
$120M
Debt
$80M
Series C
$90M
Series A (2020): $40M with participation from Perceptive Xontogeny Venture Fund
Series B (2021): $120M led by Octagon Capital, Perceptive Advisors, Surveyor Capital, RA Capital Management, and Marshall Wace
Debt (2022): $80M supported by MidCap Financial
Series C (2022): $90M featuring Drive Capital and Aisling Capital
Key Investors in Forge Biologics
Drive Capital
A venture capital firm based in Columbus that invests in exceptional founders creating the next generation of market-defining companies, focusing on growth from idea to IPO.
Aisling Capital
A leading investment firm specializing in companies that develop and commercialize innovative healthcare products, services, and technologies with over 1.8 billion in assets.
Perceptive Advisors
An investment firm managing approximately 7 billion in assets, focused on funding innovative healthcare and life sciences technologies.
What's next for Forge Biologics?
With the infusion of recent capital, Forge Biologics is positioned to scale its manufacturing footprint and enhance its technical capabilities in viral vector production. The company's strategic roadmap likely involves expanding its cleanroom capacity and investing in advanced analytical testing to meet the rigorous regulatory demands of the gene therapy market. As the firm matures, the focus will shift toward optimizing operational efficiencies and deepening its therapeutic pipeline, ensuring it remains a preferred partner for biopharma innovators seeking to bring complex genetic treatments to patients globally.
See full Forge Biologics company page
